Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN

Documenti analoghi

• Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms
  di: Huenerbein, Karlo, et al.
  Pubblicazione: (2020)
• High-resolution single-nucleotide polymorphism array-profiling in myeloproliferative neoplasms identifies novel genomic aberrations
  di: Stegelmann, Frank, et al.
  Pubblicazione: (2010)
• Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: First results from a patient survey by the German Study Group for MPN
  di: Kricheldorf, Kim, et al.
  Pubblicazione: (2021)
• Ruxolitinib-Associated Infections in Polycythemia Vera: Review of the Literature, Clinical Significance, and Recommendations
  di: Sadjadian, Parvis, et al.
  Pubblicazione: (2020)
• The Prevalence of TET2 Gene Mutations in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms (MPN): A Systematic Review and Meta-Analysis
  di: Chia, Yuh Cai, et al.
  Pubblicazione: (2021)